Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Ventricular TachycardiaAtrial Fibrillation
Interventions
DRUG

Ethanol

We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.

PROCEDURE

Ablation

The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.

Trial Locations (12)

23292

Virginia Commonwealth University, Richmond

30308

Emory University Hospital, Atlanta

55802

St. Luke's Hospital Duluth, Duluth

66160

KUMC Research Institute, Kansas City

77030

BCM/CHI St. Luke's Hospital, Houston

Houston Methodist, Houston

Houston VAMC, Houston

78705

Texas Cardiac Arrythmia Research Foundation, Austin

80045

University of Colorado School of Medicince, Denver, Denver

85013

Arizona Heart Rhythm Center, Phoenix

90033

USC Los Angeles - Keck Hopsital, Los Angeles

92123

San Diego Cardiac Center, San Diego

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The Methodist Hospital Research Institute

OTHER

NCT01898221 - Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter